LifeSci Capital analyst Cory Jubinville, PhD has maintained their bullish stance on RCKT stock, giving a Buy rating today.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Cory Jubinville, PhD has given his Buy rating due to a combination of factors related to Rocket Pharmaceuticals’ promising developments and strategic positioning in the competitive landscape. The company is actively advancing its RP-A601 program for PKP2-associated arrhythmogenic cardiomyopathy (ACM), with initial data expected to be released soon. This program is part of a competitive race with other companies, but Rocket’s approach involves a higher starting dose, which could potentially lead to more robust protein expression and favorable outcomes.
Additionally, the company has been transparent about its near-term catalysts and business updates, which were discussed in a recent dinner meeting with management. Rocket’s strategic decisions, such as the choice of dose and timing of data release, suggest a well-thought-out approach to maximizing the impact of their clinical trials. These factors, combined with the company’s current financial standing and market position, underpin the Buy rating given by Cory Jubinville, PhD.
In another report released today, J.P. Morgan also maintained a Buy rating on the stock with a $44.00 price target.